Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
Recursion: Path Forward For REC-994 Remains Despite Mixed Response
01:03pm, Wednesday, 04'th Sep 2024
Recursion Pharmaceuticals, Inc.'s REC-994 was able to show positive safety/tolerability data for the treatment of Cerebral Cavernous Malformation, along with a trend towards improvement. End-of-phase
Recursion Stock Down Despite Meeting Goal in Brain Disease Study
12:16pm, Wednesday, 04'th Sep 2024
RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.
Recursion's blood vessel disorder drug meets main goal in mid-stage study
08:11am, Tuesday, 03'rd Sep 2024
Recursion Pharmaceuticals said on Tuesday its experimental drug to treat a condition that causes blood vessel malformation met the main goal of safety and tolerability in a mid-stage study.
Is Recursion Pharmaceuticals a Warren Buffett Stock?
04:10am, Friday, 30'th Aug 2024
Recursion Pharmaceuticals lacks any of the long history of consistent performance that Buffett favors. Nonetheless, it aspires to become a business with characteristics he might like.
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
12:34pm, Sunday, 18'th Aug 2024
Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma.
Is Recursion Pharmaceuticals Stock a Buy?
09:53am, Saturday, 17'th Aug 2024
Recursion is seeking to revolutionize the way we develop drugs. If it's successful, the biotech will reap immense benefits.
Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks
07:05am, Tuesday, 13'th Aug 2024
AI holds tremendous promise for the biopharma industry. Using AI to identify candidates for new drugs is already happening.
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
04:59am, Sunday, 11'th Aug 2024
On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve
Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner
09:00am, Friday, 09'th Aug 2024
Chris Gibson, Recursion co-founder and CEO, joins 'Squawk Box' to discuss the company's $688 million acquisition of Exscientia, the use of AI in drug discovery, and more.
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript
08:25am, Friday, 09'th Aug 2024
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Chris Gibson - Co-Founder and Chief Executive Officer Najat Khan - Chief
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
05:37pm, Thursday, 08'th Aug 2024
On Thursday, Exscientia plc EXAI agreed to merge with Recursion Pharmaceuticals Inc. RXRX.
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
02:41pm, Thursday, 08'th Aug 2024
SALT LAKE CITY, Aug. 08, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Recursion (Nasdaq: RXRX), please note that in the first bullet under "Additional Corporat
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates
09:46am, Thursday, 08'th Aug 2024
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.38 per share a year ago.
Operational complementarities expected to yield annual synergies of approximately $100 million Operational complementarities expected to yield annual synergies of approximately $100 million
Biotech firm Recursion to buy smaller peer Exscientia for $688 million
07:08am, Thursday, 08'th Aug 2024
Recursion Pharmaceuticals , a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival Exscientia for $688 million in an all-stock deal, accordi
